Would you use OncoType in a postmenopausal female with HR+/HER2- with LN involvement who clinically meets RxPONDER criteria of 1-3 LN to guide the use of neoadjuvant chemotherapy?   

How would the use of Oncotype guide your management in the neoadjuvant setting?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Upper Chesapeake Hematology Oncology
In practice, how often have you found neoadjuvant ...
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice